<DOC>
	<DOCNO>NCT02744989</DOCNO>
	<brief_summary>This project aim provide proof concept transcranial direct-current stimulation ( tDCS ) treatment resistant/persistent Schizophrenia symptom . The purpose investigate effect tDCS symptom schizophrenic patient demonstrate partial response first frequently prescribe antipsychotic medication . An early optimization therapeutic strategy must constitute important factor prognosis . Hypothesize tDCS alleviate symptom patient depend clinical characteristic . In study , stimulation add-on treatment antipsychotic medication , use broad variety patient , i.e . patient varied duration illness , various symptom profile , various level treatment response . This turn allow determination extent result generalize varied patient population , well extent various therapeutic target ( e.g . different symptom dimension , cognitive performance brain connectivity ) may improve tDCS . Despite interesting preliminary result , team unable describe optimal non-invasive brain stimulation ( NIBS ) response marker . This study randomize , double blind , control , French multicenter study ( 11 center ) . The investigator plan include 138 patient persistent symptom schizophrenia . Sixty-nine subject receive active tDCS 69 subject receive sham tDCS ( placebo ) . Hypothesize lasting effect active tDCS schizophrenic symptom measure number responder , define decrease least 25 % symptom measure standardized clinical scale score ( PANSS ) baseline 10-session tDCS regimen . Furthermore , participant believe depth understanding cortical effect tDCS could constitute important step towards improve technique develop treatment response marker . An analysis effect cortical activity plasticity marker could interest approach .</brief_summary>
	<brief_title>STIM'ZO : Examining tDCS add-on Treatment Persistent Symptoms Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>1 . Diagnosis schizophrenia accord DSM 5.0 ( Diagnostic Statistical Manuel 5.0 ) criterion 2 . Presence symptom despite optimization antipsychotic dosage ( base prescriber 's judgment ) least 6 week , i.e . dosage increase consider due tolerability issue and/or judge unlikely bring sufficient clinical improvement . This operationalized minimum Negative PANSS score 20 least one item score &gt; 4 ; OR Positive PANSS score &gt; 20 least one item score &gt; 4 ( e.g . delusion hallucination ) , indicate persistent negative symptom and/or persistent positive symptom , 3 . Patient curatorship/guardianship 4 . Age 18 65 year old . 5 . Covered , right Social Security 6 . Patient understands French language 7 . Informed consent sign 1 . Other neuropsychiatric disorder ( psychiatric history assess use MINI 6.0 ( Mini International Neuropsychiatric Interview 6.0 ) ) include bipolar disorder mood depression disorder ( NB : Patients substance relate addictive disorder exclude study , data carefully record ) . 2 . Contraindications tDCS ( pacemaker brain stimulator ) and/or MRI ( neurologic stimulator , pacemaker , cardiac defibrillator , cardiac prosthesis , vascular prosthesis , intracranial clip clamp , cerebrospinal fluid derivation , metallic splinter eye ) , 3 . Increase PANSS score least 20 % screen enrollment visit 4 . Women pregnant 5 . Patients whose clinical condition require patient procedure constraint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Transcranial direct-current stimulation ( tDCS )</keyword>
	<keyword>Sham</keyword>
	<keyword>Positive Negative Syndrome Scale ( PANSS )</keyword>
	<keyword>Functional Magnetic Resonance Imaging ( fRMI )</keyword>
	<keyword>Brain-Derived-Neurotrophic Factor ( BDNF )</keyword>
</DOC>